ABOUT US
Travere Therapeutics is a biopharmaceutical company whose mission is to identify, develop and deliver life-changing therapies to people living with rare disease.
We are driven to deliver safe and effective therapies to patients as quickly as possible. To do this, we are advancing a pipeline of potential first-in-class medicines targeting rare diseases with significant unmet needs and oftentimes no approved treatment options.
Our efforts are led by late-stage development programs of sparsentan, which is a novel product candidate targeting rare kidney diseases – focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN).
We are also partnering with leaders in patient advocacy and the National Institutes of Health (NIH) on earlier-stage development work in rare liver diseases. In addition, pegtibatinase (TVT-058), the first potential disease-modifying therapy for the treatment of classical homocystinuria (HCU), is in Phase 1/2 development.
Today we aim to help patients with our four approved commercial therapies, Chenodal® (chenodiol), Cholbam® (cholic acid), Thiola® (tiopronin), and Thiola EC® (tiopronin) delayed-release tablets. We are committed to broad access for our FDA-approved therapies, and we provide personalized clinical support services through the Total Care Hub. We also sponsor diagnostic testing at no cost to qualified patients to help accurately diagnose a variety of disorders.
Because of our patient-centered purpose and recognition that rare disease has no borders, we supported the creation of the Rare Disease Network at Children’s National Rare Disease Institute (CNRDI). The network exists to improve rare disease care in the US and internationally through innovative digital medicine technology and partnerships with rare disease experts.
In our commitment to support caregivers of people living with rare disease, we worked with NORD to establish the Rare Caregiver Respite Program, and with the National Alliance of Caregivers to better understand and help meet the needs of rare caregivers.
We also supported the first-ever Diversity Inclusion Advocacy Fellowship at the EveryLife Foundation for Rare Diseases to increase the representative diversity of patient voices and to engage low income and minority communities in advocacy.
RET153
Travere Therapeutics Announces Presentations of Abstracts at the 59th ERA Congress
NewsSAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced presentations including baseline characteristics for patients enrolled in the ongoing pivotal Phase 3 PROTECT and DUPLEX studies of sparsentan in IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS), respectively, at the 59th European Renal Association (ERA) Congress. The Company and its collaborators will also present nonclinical data examining the renal protective effects of sparsentan compared to controls. ERA is being held live in Paris, France, and virtually May 19-22, 2022.
Read the full press release >